drugset / Trial / NCT05441046
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.
Timeline
- Start
- 2022-06-07
- Primary completion
- 2024-06
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Genakumab | Monoclonal antibody | 100 mg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |